LUCENT: Survey data on patient and healthcare provider experiences of mirikizumab administration
In this medfyle
The LUCENT trials collected information about patient and HCP experiences of mirikizumab administration. Data presented at ECCO 2024 explore the satisfaction reported for IV and SC routes, and compare patient and HCP perceptions.
This Medfyle was published more than two years ago. More recent Medfyle on this topic may now be available.
About this Medfyle
©2024 Medfyle. All rights reserved.
Source: Clemow D, Radawski C, Milata J, et al. P781 Mirikizumab administration experience from Ulcerative Colitis patients and healthcare providers: Survey data from the LUCENT clinical program. J Crohns Colitis 2024;18(suppl1):jjad212.0911 [P781]
The information and data provided is for information purposes only.
The author(s) of the original article had no involvement in the creation of this content.
